| pubmed-article:18835709 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18835709 | lifeskim:mentions | umls-concept:C0034250 | lld:lifeskim |
| pubmed-article:18835709 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
| pubmed-article:18835709 | lifeskim:mentions | umls-concept:C1152568 | lld:lifeskim |
| pubmed-article:18835709 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:18835709 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:18835709 | pubmed:issue | 21 | lld:pubmed |
| pubmed-article:18835709 | pubmed:dateCreated | 2009-10-30 | lld:pubmed |
| pubmed-article:18835709 | pubmed:abstractText | A novel series of pyrazolo[1,5-b]pyridazines have been synthesized and identified as cyclin dependant kinase inhibitors potentially useful for the treatment of solid tumors. Modification of the hinge-binding amine or the C(2)- and C(6)-substitutions on the pyrazolopyridazine core provided potent inhibitors of CDK4 and demonstrated enzyme selectivity against VEGFR-2 and GSK3beta. | lld:pubmed |
| pubmed-article:18835709 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18835709 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18835709 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18835709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18835709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18835709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18835709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18835709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18835709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18835709 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18835709 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:18835709 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:18835709 | pubmed:author | pubmed-author:DavisStephen... | lld:pubmed |
| pubmed-article:18835709 | pubmed:author | pubmed-author:GriffinRobert... | lld:pubmed |
| pubmed-article:18835709 | pubmed:author | pubmed-author:PriceDaniel... | lld:pubmed |
| pubmed-article:18835709 | pubmed:author | pubmed-author:HassellAnne... | lld:pubmed |
| pubmed-article:18835709 | pubmed:author | pubmed-author:KnickVictoria... | lld:pubmed |
| pubmed-article:18835709 | pubmed:author | pubmed-author:VealJames MJM | lld:pubmed |
| pubmed-article:18835709 | pubmed:author | pubmed-author:ShewchukLisa... | lld:pubmed |
| pubmed-article:18835709 | pubmed:author | pubmed-author:StevensKirk... | lld:pubmed |
| pubmed-article:18835709 | pubmed:author | pubmed-author:PeelMichael... | lld:pubmed |
| pubmed-article:18835709 | pubmed:author | pubmed-author:RenoMichael... | lld:pubmed |
| pubmed-article:18835709 | pubmed:author | pubmed-author:AlbertiJennif... | lld:pubmed |
| pubmed-article:18835709 | pubmed:author | pubmed-author:Kane-CarsonLa... | lld:pubmed |
| pubmed-article:18835709 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18835709 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:18835709 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:18835709 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18835709 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18835709 | pubmed:pagination | 5758-62 | lld:pubmed |
| pubmed-article:18835709 | pubmed:dateRevised | 2011-11-2 | lld:pubmed |
| pubmed-article:18835709 | pubmed:meshHeading | pubmed-meshheading:18835709... | lld:pubmed |
| pubmed-article:18835709 | pubmed:meshHeading | pubmed-meshheading:18835709... | lld:pubmed |
| pubmed-article:18835709 | pubmed:meshHeading | pubmed-meshheading:18835709... | lld:pubmed |
| pubmed-article:18835709 | pubmed:meshHeading | pubmed-meshheading:18835709... | lld:pubmed |
| pubmed-article:18835709 | pubmed:meshHeading | pubmed-meshheading:18835709... | lld:pubmed |
| pubmed-article:18835709 | pubmed:meshHeading | pubmed-meshheading:18835709... | lld:pubmed |
| pubmed-article:18835709 | pubmed:meshHeading | pubmed-meshheading:18835709... | lld:pubmed |
| pubmed-article:18835709 | pubmed:meshHeading | pubmed-meshheading:18835709... | lld:pubmed |
| pubmed-article:18835709 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18835709 | pubmed:articleTitle | Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase inhibitors. | lld:pubmed |
| pubmed-article:18835709 | pubmed:affiliation | Department of Oncology, GlaxoSmithKline, Research Triangle Park, NC 27709, USA. Kirk.L.Stevens@gsk.com | lld:pubmed |
| pubmed-article:18835709 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:18835709 | lld:chembl |
